Eisenmenger Syndrome: A Comprehensive Overview

991 Words2 Pages

Introduction
Eisenmenger Syndrome (ES) is a heart defect that was first giving the name in 1897 (Fukushima, 2015). This syndrome happens when the birth defect is not treated before the lungs’ arteries become damaged. Eisenmenger Syndrome is named after Victor Eisenmenger a man who had a patient who showed symptoms such as, breathing complications and skin that was turning a bluish color. The autopsy of this patient lead him to discover a ventricular septal defect [VSD] (El-Chami, 2014), that causes a hole in the wall on the right and left ventricular. This is the defect that begins when signaling for pulmonary artery hypertension, which progresses into more advanced stages of ES. This birth defect eventually causes patients to have various …show more content…

This syndrome increase blood flow causes the heart to pump blood to the lungs at an increasing rate and destroys the blood vessels in the lungs. Several Heart defects that causes disorder is ventricular septal defect (VSD), atrial septal defect (ASD), Patent ductus arteriosus (PDS), and Atrioventricular canal defect (ACD) (Mayo Clinic,2016) This hole usually causes symptoms that include blue or gray skin pigments, shortness of breath, extreme fatigue, chest pains, racing or skipped heart beats, and dizziness. Other symptoms include coughing up blood, swelling in the abdominal region, and numb and/or enlarged fingers and toes. Some of the way ER syndrome can be diagnosed are Chest X-ray are used for heart and pulmonary artery enlargement. Electrocardiogram (ECG) electrical activity of the heart that help test for heart defect that are caused by ES, Echocardiogram is normally used for listing to sound of the heart during, but during ER testing it helps to see if the patient have a heart defect, Magnetic resonance imaging (MRI) is used to take images of blood vessels and lungs and blood test is use to check blood count, which ES would make it …show more content…

For example, heart and lung transplants. This is a solution if a patient’s hole in the heart cannot be healed or helped with another form treatment. Several different targeted therapies have been done to improve health of ES patients. Disease-targeting therapies have proven to be successful in Idiopathic Pulmonary Arterial Hypertension (IPAH) and have been analyzed to in their effectiveness against ES. Prostanoid therapy in patients with ES has also shown the possibility that therapy may improve oxygen saturation, exercise capacity, and even shows a decrease Pulmonary Vascular Resistance (PVR). This is backed by a study with eight patients that have ES, these results were after 3 months of therapy. Another study is being done in a method called Vasodilator therapy. In these case studies, a drug name prostacyclin improved hemodynamics sufficiently enough to ensure ES patients for surgery to repair the cardiac lesion. Other studies have shown that Phosphodiesterase Type-5 Inhibitors, were used in patients with ES. In these studies, observation over a six-month period allowed the researchers to see improvements in oxygen saturation and cardiopulmonary hemodynamics (Beghetti and Galiè, 2009). Research from these studies is also being combined with different medical treatment to target therapies and is it possible to reverse pulmonary vascular

More about Eisenmenger Syndrome: A Comprehensive Overview

Open Document